Literature DB >> 17623735

Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis.

B I Glanz1, C M Holland, S A Gauthier, E L Amunwa, Z Liptak, M K Houtchens, R A Sperling, S J Khoury, C R G Guttmann, H L Weiner.   

Abstract

Cognitive dysfunction is common in patients with multiple sclerosis (MS), and has been associated with MRI measures of lesion burden and atrophy. Little is known about the prevalence of cognitive impairment in patients with early MS. The associations between cognitive impairment and MRI measures of disease severity early in the disease course are also unclear. This study used a brief battery of cognitive tests to determine the prevalence and pattern of cognitive impairment in patients with clinically isolated syndromes or newly diagnosed MS. The associations between cognitive impairment and MRI measures of disease severity early in the disease course were also examined. Ninety-two patients with clinically isolated syndromes or the diagnosis of MS within the last 3 years participating in the CLIMB study underwent a neurologic examination, neuropsychological evaluation and MRI at 1.5 T. Forty-nine percent of patients were impaired on one or more cognitive measures. There were no significant correlations between cognitive scores and MRI measures of disease severity including total T2 lesion volume, normal appearing white matter volume, grey matter volume, and brain parenchymal fraction. These findings suggest that cognitive impairment may predate the appearance of gross structural abnormalities on MRI and serve as an early marker of disease activity in MS.

Entities:  

Mesh:

Year:  2007        PMID: 17623735     DOI: 10.1177/1352458507077943

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  51 in total

Review 1.  Cognitive impairment in early stages of multiple sclerosis.

Authors:  Maria Pia Amato; E Portaccio; B Goretti; V Zipoli; B Hakiki; M Giannini; L Pastò; L Razzolini
Journal:  Neurol Sci       Date:  2010-11       Impact factor: 3.307

2.  Subcutaneous Interferon Beta-1a Has a Positive Effect on Cognitive Performance in Mildly Disabled Patients with Relapsing-Remitting Multiple Sclerosis: 2-Year Results from the COGIMUS Study.

Authors:  Francesco Patti; Maria Pia Amato; Stefano Bastianello; Luisa Caniatti; Elisabetta Di Monte; Fausto Lijoi; Benedetta Goretti; Silvia Messina; Orietta Picconi; Maria Rosalia Tola; Maria Trojano
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

3.  Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome.

Authors:  Tomas Uher; Jana Blahova-Dusankova; Dana Horakova; Niels Bergsland; Michaela Tyblova; Ralph H B Benedict; Tomas Kalincik; Deepa P Ramasamy; Zdenek Seidl; Jesper Hagermeier; Manuela Vaneckova; Jan Krasensky; Eva Havrdova; Robert Zivadinov
Journal:  J Neurol       Date:  2014-06-22       Impact factor: 4.849

4.  The Need for Screening, Assessment, and Treatment for Cognitive Dysfunction in Multiple Sclerosis: Results of a Multidisciplinary CMSC Consensus Conference, September 24, 2010.

Authors:  Frederick W Foley; Ralph H B Benedict; Elizabeth S Gromisch; John Deluca
Journal:  Int J MS Care       Date:  2012

5.  Ocular motor measures of cognitive dysfunction in multiple sclerosis I: inhibitory control.

Authors:  Meaghan Clough; Lynette Millist; Nathaniel Lizak; Shin Beh; Teresa C Frohman; Elliot M Frohman; Owen B White; Joanne Fielding
Journal:  J Neurol       Date:  2015-04-09       Impact factor: 4.849

6.  Evolving expectations around early management of multiple sclerosis.

Authors:  Ralf Gold; Jerry S Wolinsky; Maria Pia Amato; Giancarlo Comi
Journal:  Ther Adv Neurol Disord       Date:  2010-11       Impact factor: 6.570

7.  Spatial navigation in early multiple sclerosis: a neglected cognitive marker of the disease?

Authors:  Eva Němá; Adam Kalina; Tomáš Nikolai; Martin Vyhnálek; Eva Meluzínová; Jan Laczó
Journal:  J Neurol       Date:  2020-07-22       Impact factor: 4.849

Review 8.  Risk factors for and management of cognitive dysfunction in multiple sclerosis.

Authors:  Ralph H B Benedict; Robert Zivadinov
Journal:  Nat Rev Neurol       Date:  2011-05-10       Impact factor: 42.937

9.  Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.

Authors:  Francesco Patti
Journal:  Patient Prefer Adherence       Date:  2010-02-04       Impact factor: 2.711

10.  Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis.

Authors:  James M Stankiewicz; Bonnie I Glanz; Brian C Healy; Ashish Arora; Mohit Neema; Ralph H B Benedict; Zachary D Guss; Shahamat Tauhid; Guy J Buckle; Maria K Houtchens; Samia J Khoury; Howard L Weiner; Charles R G Guttmann; Rohit Bakshi
Journal:  J Neuroimaging       Date:  2011-04       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.